- Home
- GROW vs CVM Comparison
GROW vs CVM Comparison
Compare GROW & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | CVM |
|---|---|---|
| Founded | 1968 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 30.1M |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GROW | CVM |
|---|---|---|
| Price | $2.83 | $1.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 10.9K | ★ 265.6K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | ★ 900.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $14,399,000.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.92 | ★ N/A |
| Revenue Growth | 32.77 | ★ 65.45 |
| 52 Week Low | $2.23 | $0.89 |
| 52 Week High | $3.65 | $10.16 |
Technical Indicators
Market Signals| Indicator | GROW | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 45.59 |
| Support Level | $2.45 | $1.01 |
| Resistance Level | $2.75 | $2.83 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 10.53 | 3.86 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.